FDA adds eye-condition warning to Ozempic, Zepbound and other GLP-1 drugs
The FDA announced a new label warning for GLP-1 medications including Ozempic and Zepbound, flagging a rare eye condition that can cause sudden vision changes. The agency says the condition carries a risk of permanent damage in some patients.